Catastrophic consequences secondary to psychotropic drugs, part 1

Journal of Psychosocial Nursing and Mental Health Services

Volumn 35, Issue 4, 1997, Pages 41-45

  Keltner, Norman L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NURSING; NURSING ASSESSMENT; REVIEW;

ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; NURSING ASSESSMENT; PSYCHOTROPIC DRUGS; SEROTONIN UPTAKE INHIBITORS;

EID: 0031111826     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Blair, D.T. (1990). Risk management for extrapyramidal symptoms. Quality Review Bulletin, 16, 116-124.
2. Bodner, R.A., Lynch, T., Lewis, L., & Kahn, D. (1995). Serotonin syndrome. Neurology, 45, 219-223.
3. Brennan, D., MacManus, M., & Howe, J. (1988). Neuroleptic malignant syndrome without neuroleptics (letter). British Journal of Psychiatry, 14, 144-145.
4. Buckley, F.F., & Hutchinson, M. (1995). Neuroleptic malignant syndrome. Neurological and Neurosurgical Psychiatry, 58, 271-273.
5. Cain, J. (1992). Poor response to fluoxetine: Underlying depression, serotonergic overstimulation, or a "therapeutic window"? Journal of Clinical Psychiatry, 53, 272-277.
6. Caroff, S.N., & Mann, S.C. (1988). Neuroleptic malignant syndrome. Psychopharmacology Bulletin, 24, 25-29.
7. Caroff, S.N., & Mann, S.C. (1993). Neuroleptic malignant syndrome. Medical Clinics of North America, 71, 185-202.
8. Delay, J., & Deniker, P. (1952). The treatment of excitement and agitation states by a method of medicine derived from hibemotherapy. Annals of Medicine and Psychology, 110, 267-275.
9. Delay, J., Pichot, P., Lemperier, M.T., Ellisalde, B., & Peigner, F. (1960). Un neuroleptic majeur non phenothiazineque et non reserpinique, l'halidol, dans le traitment des psychoses. Annals of Medicine and Psychology (Paris), 118, 145-152.
10. Gelenberg, A.J., Bellinghausen, B., Wojcik, J.S., Falk, W.E., & Sachs, G.S. (1988). A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. American Journal of Psychiatry, 145, 517-518.
11. Hollister, L. (1994). New psychotherapeutic drugs. Journal of Clinical Psychopharmacology, 14(10), 50-63.
12. Hooper, J.F., Herren, C.K., & Goldwasser, H. (1989). Neuroleptic malignant syndrome. Journal of Psychosocial Nursing and Mental Health Services, 27, 13-17.
13. Insel, R., Roy, B., Cohen, R., & Murphy, D. (1982). Possible development of the serotonin syndrome in man. American Journal of Psychiatry, 139, 954-955.
14. Keck, P.E., Pope, H.G., & McElroy, S.L. (1991). Declining frequency of neuroleptic malignant syndrome in a hospital population. American Journal of Psychiatry, 148, 880-882.
15. Keltner, N.L. (1985). Psychotherapeutic management: A model for nursing practice. Perspectives in Psychiatric Care, 23, 125-130.
16. Keltner, N.L., & Harris, C.P. (1994). Serotonin syndrome: A case of fatal SSRI/MAOI interaction. Perspectives in Psychiatric Care, 30, 26-31.
17. Keltner, N.L., & McIntyre, C. (1985). Neuroleptic malignant syndrome. Journal of Neuroscience Nursing, 17, 363-366.
18. Keltner, N.L., Schwecke, L., & Bostrom, C. (1995). Psychiatric nursing. St. Louis, Mo: C.V. Mosby.
19. Kline, S., Mauro, L., Scala-Barnett, D., & Zick, D. (1989). Serotonin syndrome versus neuroleptic malignant as a cause of death. Clinical Pharmacology, 8, 510-514.
20. Lappin, R.I., & Auchincloss, E.L. (1994). Treatment of the serotonin syndrome with cyproheptadine. New England Journal of Medicine, 331, 1021-1022.
21. Laraia, M., Beeber, L., Callwood, G., Caverly, S., Clement, J.A., Gary, F., Keltner, N.L., Nihart, M.A., Scahill, L., Simmons-Alling, S., Stanley, S., & Talley, S. (1994). Psychiatric Mental Health Nursing Psychopharmacology Project. Washington, DC: American Nurses Association.
22. Meltzer, H. (1991). The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin, 17, 263-279.
23. Nimmo, S., Kennedy, B., Tullett, W., Blyth, A., & Dougall, J. (1993). Drug-induced hyperthermia. Anaesthesia, 48, 892-895.
24. Oates, J.A., & Sjoerdsma, A. (1960). Neurologic effecls of tryplophan in patients receiving a monoamine oxidase inhibitor. Neurology, 10, 1076-1078.
25. Ooi, T. (1991). The serotonin syndrome (letter). Anaesthesia, 46, 507-508.
26. Persing, J.S. (1994). Neuroleptic malignant syndrome: An overview. South Dakota Journal of Medicine, 47(2), 51-55.
27. Rapport, M., Green, A., & Page, I. (1948). Serum vasoconstrictor (serotonin): IV. Isolation and characterization. Journal of Biological Chemistry, 176, 1243-1251.
28. Reeves, R.R., & Bullen, J.A. (1995). Serotonin syndrome produced by paroxetine and low-dose trazodone (letter). Psychosomatic Disorders, 36, 159-160.
29. Schatzberg, A., & Rothschild, A. (1992). Serotonin activity in psychotic (delusional) major depression. Journal of Clinical Psychiatry, 53(10, suppl), 52-55.
30. Shalev, A., Hermesh, H., & Munitz, H. (1989). Mortality from neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 50(1), 18-25.
31. Shalev, A., & Munitz, H. (1986). The neuroleptic malignant syndrome: Agent and host interaction. Acta Psychiatrica Scandinavica, 73, 337-347.
32. Sternbach, J. (1991). The serotonin syndrome. American Journal of Psychiatry, 148, 705-712.
33. Sugarman, J.R. (1984). Management of lithium toxicity. Family Practitioner, 18, 347-351.
34. Tueth, M.J. (1994). Emergencies caused by side effects of psychiatric medication. American Journal of Emergency Medicine, 12, 212-216.
35. Velamoor, V.R., Norman, R.M.G., Caroff, S.N., Mann, S.C., Sullivan, K.A., & Antelo, R.E. (1994). Progression of symptoms in neuroleptic malignant syndrome. Journal of Nervous and Mental Diseases, 182, 168-173.